Hassan Lakkis, PhD

Intra-Cellular Therapies, a Johnson & Johnson Company, Bedminster, New Jersey

  • 1Article
  • 2025Active
  • 6Collaborators
  • 4Citations

About

Hassan Lakkis, PhD is affiliated with Intra-Cellular Therapies, a Johnson & Johnson Company, Bedminster, New Jersey. Hassan Lakkis has contributed 1 peer-reviewed article published across the Journal of Clinical Psychiatry and the Primary Care Companion for CNS Disorders in 2025. Their work focuses on Depression (MDD).

Publications

JCP
Lumateperone as Adjunctive Therapy in MDD: A Randomized, Double-Blind, Phase 3 Trial
Original Research

Lumateperone as Adjunctive Therapy in MDD: A Randomized, Double-Blind, Phase 3 Trial

August 25, 2025

In patients with MDD with inadequate antidepressant response, adjunctive lumateperone 42 mg significantly improved depression symptoms and severity versus adjunctive placebo, and it was generally well tolerated.
, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe